Long-term disease control and safety with the anti-CCR4 antibody mogamulizumab: Post-hoc analyses from the MAVORIC trial of patients with previously treated cutaneous T-cell lymphoma.
Dermatol Ther
; 35(8): e15634, 2022 08.
Article
in En
| MEDLINE
| ID: mdl-35695215
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Skin Neoplasms
/
Lymphoma, T-Cell, Cutaneous
Limits:
Humans
Language:
En
Journal:
Dermatol Ther
Journal subject:
DERMATOLOGIA
Year:
2022
Document type:
Article
Affiliation country:
France
Country of publication:
United States